CD8A and non-small cell lung carcinoma: Expanding on our previous findings of predictive changes in immune cell subsets and genetic parameters [22], the current study confirms and extends the observation of a marked post-treatment increase in activated effector memory CD8 T cells among late-stage NSCLC patients responding to PD-1/PD-L1 blockade [22].